A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Condition(s) studied

Investigational drug(s) / intervention(s)

Elranatamab: subcutaneous

Daratumumab: Daratumumab / hyaluronidase, subcutaneous

Pomalidomide: oral

Dexamethasone: oral

Study summary

The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study.

Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab.

People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab.

Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab.

All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.

Eligibility

Primary outcome measure(s)

• Part 1 Safety Lead-In: Incidence of dose limiting toxicities — First 42 days after first elranatamab dose
• Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria — From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months
• Part 3: Frequency of treatment-emergent adverse events — First 84 days after first elranatamab dose

Trial sites (237)

+ 197 more sites — see the full list on the official registry below.

On this site

More Pfizer trials in Italy

Other trials for the same condition